Design of novel monoamine oxidase-B inhibitors based on piperine scaffold: Structure-activity-toxicity, drug-likeness and efflux transport studies

被引:30
作者
Chavarria, Daniel [1 ,2 ]
Fernandes, Carlos [1 ]
Silva, Vera [1 ,3 ]
Silva, Catia [1 ]
Gil-Martins, Eva [1 ,3 ]
Soares, Pedro [1 ]
Silva, Tiago [1 ,2 ]
Silva, Renata [3 ]
Remiao, Fernando [3 ]
Oliveira, Paulo J. [2 ]
Borges, Fernanda [1 ]
机构
[1] Univ Porto, Fac Sci, Dept Chem & Biochem, CIQUP, Porto, Portugal
[2] Univ Coimbra, UC Biotech, CNC Ctr Neurosci & Cell Biol, Biocant Pk, Cantanhede, Portugal
[3] Univ Porto, Fac Pharm, Dept Biol Sci, UCIBIO,REQUIMTE,Lab Toxicol, Porto, Portugal
关键词
Parkinson's disease; Piperine; Monoamine oxidase; Structure-activity-toxicity relationship; P-gp; BLOOD-BRAIN-BARRIER; P-GLYCOPROTEIN; PERMEABILITY; PREVENT; LONGUM; CELLS; MODEL; HPLC;
D O I
10.1016/j.ejmech.2019.111770
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Piperine has been associated with neuroprotective effects and monoamine oxidase (MAO) inhibition, thus being an attractive scaffold to develop new antiparkinsonian agents. Accordingly, we prepared a small library of piperine derivatives and screened the inhibitory activities towards human MAO isoforms (hMAO-A and hMAO-B). Structure-activity relationship (SAR) studies pointed out that the combination of alpha-cyano and benzyl ester groups increased both potency and selectivity towards hMAO-B. Kinetic experiments with compounds 7, 10 and 15 indicated a competitive hMAO-B inhibition mechanism. Compounds 15 and 16, at 10 mu M, caused a small but significant decrease in P-gp efflux activity in Caco-2 cells. Compound 15 stands out as the most potent piperine-based hMAO-B inhibitor (IC50 = 47.4 nM), displaying favourable drug-like properties and a broad safety window. Compound 15 is thus a suitable candidate for lead optimization and the development of multitarget-directed ligands. (C) 2019 Elsevier Masson SAS. All rights reserved.
引用
收藏
页数:12
相关论文
共 58 条
[1]  
[Anonymous], [No title captured]
[2]  
Arsovska E, 2014, ACTA CHIM SLOV, V61, P637
[3]   Blood-Brain Barrier P-Glycoprotein Function in Neurodegenerative Disease [J].
Bartels, A. L. .
CURRENT PHARMACEUTICAL DESIGN, 2011, 17 (26) :2771-2777
[4]   Fine-tuning the neuroprotective and blood-brain barrier permeability profile of multi-target agents designed to prevent progressive mitochondrial dysfunction [J].
Benfeito, S. ;
Oliveira, C. ;
Fernandes, C. ;
Cagide, F. ;
Teixeira, J. ;
Amorim, R. ;
Garrido, J. ;
Martins, C. ;
Sarmento, B. ;
Silva, R. ;
Remiao, F. ;
Uriarte, E. ;
Oliveira, P. J. ;
Borges, F. .
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2019, 167 :525-545
[5]   Neuroprotective effects of alkaloids from Piper longum in a MPTP-induced mouse model of Parkinson's disease [J].
Bi, Ying ;
Qu, Peng-Cheng ;
Wang, Qing-Song ;
Zheng, Li ;
Liu, Hao-Long ;
Luo, Rong ;
Chen, Xiao-Qing ;
Ba, Yin-Ying ;
Wu, Xia ;
Yang, Hui .
PHARMACEUTICAL BIOLOGY, 2015, 53 (10) :1516-1524
[6]   Structure of human monoamine oxidase B, a drug target for the treatment of neurological disorders [J].
Binda, C ;
Newton-Vinson, P ;
Hubálek, F ;
Edmondson, DE ;
Mattevi, A .
NATURE STRUCTURAL BIOLOGY, 2002, 9 (01) :22-26
[7]   Safinamide: A Review in Parkinson's Disease [J].
Blair, Hannah A. ;
Dhillon, Sohita .
CNS DRUGS, 2017, 31 (02) :169-176
[8]   Thio- and aminocaffeine analogues as inhibitors of human monoamine oxidase [J].
Booysen, Hermanus P. ;
Moraal, Christina ;
Terre'Blanche, Gisella ;
Petzer, Anel ;
Bergh, Jacobus J. ;
Petzer, Jacobus P. .
BIOORGANIC & MEDICINAL CHEMISTRY, 2011, 19 (24) :7507-7518
[9]   High-throughput liquid chromatography/mass spectrometry method for the determination of the chromatographic hydrophobicity index [J].
Camurri, G ;
Zaramella, A .
ANALYTICAL CHEMISTRY, 2001, 73 (15) :3716-3722
[10]   A Method to Predict Blood-Brain Barrier Permeability of Drug-Like Compounds Using Molecular Dynamics Simulations [J].
Carpenter, Timothy S. ;
Kirshner, Daniel A. ;
Lau, Edmond Y. ;
Wong, Sergio E. ;
Nilmeier, Jerome P. ;
Lightstone, Felice C. .
BIOPHYSICAL JOURNAL, 2014, 107 (03) :630-641